Home
Orphan Drugs and Rare Diseases
19 October - 20 October 2015
Orphan Drugs and Rare Diseases

Several thousand different types of rare diseases and disorders exist, with more being discovered each day. As a result, in recent years, the interest for rare diseases has grown throughout the entire medical community. However, the road to an approved orphan drug is a long, challenging and costly one with many challenges on the way including regulatory, financial, sustainability and pricing and reimbursement issues. 

 

 

Returning for its fourth year and following on from the major success of previous events, SAE Media Group are proud to present the 4th annual Orphan Drugs and Rare Diseases Conference, 19th – 20th October 2015, London, UK. Through a series of interactive presentations and panel discussions, join us and learn how payers, pharmaceutical, biotech, patient organisations and academia are structuring to participate in and leverage the growing orphan market.


Key topics include:

• Development of ultra-orphan drugs to prevent, diagnose and treat rare diseases
• Creating strategies for overcoming the challenges for reimbursement of orphan and ultra orphan drugs
• Discover how gene therapy is a very real factor in clinical trials
• Creating workable partnerships for future development of drugs
  

And much more!

FEATURED SPEAKERS

Alastair Kent OBE

Alastair Kent OBE

Director, Director Genetic Alliance UK, Chair of Rare Disease UK (RDUK)
David Boothe

David Boothe

Global Commercial Leader – GSK Rare Diseases, GSK
Dr Michael Skynner

Dr Michael Skynner

Head of Rare Disease Alliances, Rare Disease Research Unit, Pfizer
Dr Nicolas Sireau

Dr Nicolas Sireau

Chairman and CEO, AKU Society

Alastair Kent OBE

Director, Director Genetic Alliance UK, Chair of Rare Disease UK (RDUK)
Alastair Kent OBE

Anders Waas

Chief Executive Officer, Tikomed
Anders Waas

Christine Lavary

Chief Executive, MPS Society UK
Christine Lavary

David Boothe

Global Commercial Leader – GSK Rare Diseases, GSK
David Boothe

Dr Carlos Camozzi

Chief Medical Officer, Orphazyme
Dr Carlos Camozzi

Dr Didier Caizergues

Head of regulatory Affairs Department, International Regulatory Affairs department, GENETHON
Dr Didier Caizergues

Dr Diego Ardigo

ATMP Project Leader, Corporate Drug Development, R&D, Chiesi Farmaceutici S.p.A.
Dr Diego Ardigo

Dr Michael Skynner

Head of Rare Disease Alliances, Rare Disease Research Unit, Pfizer
Dr Michael Skynner

Dr Nicolas Sireau

Chairman and CEO, AKU Society
Dr Nicolas Sireau

Helena Baker

Vice President of Nursing , The Medical Research Network
Helena Baker

Helena Baker is the Vice President of Nursing at the MRN, where she is responsible for all aspects of the company's nursing service delivery, in addition to clinical governance, nursing strategy and managing clinical risk.
She is currently managing the development of an international nurse training and development program and plans for international expansion of the business into emerging markets across the world.
As a registered nurse, Helena has 22 years of experience in nursing and healthcare, including roles at The Royal London in Whitechapel, Ferring Pharmaceuticals Ltd, and St Bartholemew's. In 1998, Helena founded Helena Baker Associates, working as a healthcare analyst to the pharmaceutical industry, before joining Healthcare at Home and then MRN in 2007.
 

John Maddox

Managing Director, Infusion Pharma Consulting LLC
John Maddox

Professor Bobby Gasper

Professor of Paediatrics and Immunology, Consultant in Paediatric Immunology, Head, Rare Diseases Theme Head, , University College London, Institute of Child Health
Professor Bobby Gasper

Stephane Demotz

Founder, DORPHAN S.A., Switzerland
Stephane Demotz

Terence Hoey

CEO, The Ultra Rare Diseases, Disorder & Disabilities Foundation
Terence Hoey

Tim Miller

President & CEO, Abeona Therapeutics
Tim Miller

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Opening remarks and introductions

Colette Hamilton

Colette Hamilton, Global Vice President Health Economics and Reimbursement, Evidence fof Access

clock

9:10

The Pricing Controversy

• Price vs cost – payer perspectives 
• Label creep
• The relationship between pricing policy and patient access
• Case studies
• Attaining WIN-WIN
 

clock

9:50

Payor Trends and Implications

• Trends in payer policy and coverage
• Trends in HTA evaluation 
• Understanding conditions for reimbursement
• Implications for industry
 

clock

10:30

Morning Coffee

clock

11:00

Redefining Value

• Evolving understanding of benefit versus cost
• QALY limitations and alternatives
• Adoption of multi-criteria decision analysis
• Solutions that work for patients, doctors, industry and payers
 

clock

11:40

Evidence Generation

• Addressing challenges in demonstrating safety and efficacy when working with low patient numbers
• Creative ways to assimilate data
• The opportunities and limitations of real world evidence
• Evidence generation solutions for orphan drugs
 

clock

12:20

Closing remarks

clock

12:30

End of workshop

clock

13:30

Registration

clock

14:00

Opening remarks and introductions

clock

14:10

Regulatory framework & how to successfully transform regulatory strategies into practical clinical development planning

Steve Pinder

Steve Pinder, Director, Envestia

• Brief outline of Orphan Drug regulations
• Common misinterpretations of orphan drug legislations
• Regulatory strategies vs Clinical development strategies 
 

clock

15:30

Coffee

clock

15:45

The crucial role of patient advocacy groups in a successful orphan drug development program

Nicolas Sireau

Nicolas Sireau, Chairman and CEO, AKU Society

• Public/private funding & crowd funding
• Role of patient advocacy groups in rare disease clinical trials 
 

clock

16:30

Lowering patient burden & practical / logistical challenges to ensure successful clinical study execution

Christa Verburg

Christa Verburg, Senior Clinical Project Manage, PSR Orphan Experts

• Patient recruitment & retention strategies
• Lowering patient burden
• Logistical / practical challenges
 

clock

17:15

Closing remarks

clock

17:30

End of workshop

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Dr Nicolas Sireau

Dr Nicolas Sireau, Chairman and CEO, AKU Society

clock

9:10

Big phama and the orphan drug industry

Dr Carlos Camozzi

Dr Carlos Camozzi, Chief Medical Officer, Orphazyme

• Analysing the role of big pharma in the emerging orphan drug industry
• Where is their focus going and what does this mean for the industry long term
• What is their current perspective and what is the next step? 
 

clock

9:50

Patient Organisations Working Collaboratively with the Challenges of Reimbursement from a Patient Perspective

Christine Lavary

Christine Lavary, Chief Executive, MPS Society UK

• A Collaborative Approach
• Working in Partnership with Industry
• Reimbursement and Access to High Cost Therapies
 

clock

10:30

Morning Coffee

clock

11:00

DevelopAKUre – a patient-led clinical trial

Dr Nicolas Sireau

Dr Nicolas Sireau, Chairman and CEO, AKU Society

• How to work closely with patients to develop a clinical trial programme
• Strategies for recruiting patients for successful trials
• Using social media in clinical trials
• How to put together successful collaborations
 

clock

11:40

Importance of Collaboration in Rare Disease Research

Dr Michael Skynner

Dr Michael Skynner , Head of Rare Disease Alliances, Rare Disease Research Unit, Pfizer

• Working in rare disease research presents specific challenges
• One approach to address these challenges is through collaboration
• Pfizer’s collaborative approaches in the area of drug discovery
 

clock

12:20

Networking Lunch

clock

13:30

Development of a drug for GM1-gangliosidosis by a non-profit foundation

Stephane Demotz

Stephane Demotz, Founder, DORPHAN S.A., Switzerland

• Discovery phase: working with academic laboratories and spin-off of a commercial entity
• Preclinical development: outsourcing to commercial service providers vs. academic laboratories
• Clinical development: selecting the right partners for a micro-company
• Financing the development of a drug for a rare disease
 

clock

14:10

Panel Discussion: Is global collaboration the answer to reaching all potential patients?

• Is this the way forward for reaching patients and developing and new treatments?
• What resources would be required?
• How would this be coordinated?
 

Dr Nicolas Sireau

Dr Nicolas Sireau, Chairman and CEO, AKU Society

Professor Bobby Gasper

Professor Bobby Gasper, Professor of Paediatrics and Immunology, Consultant in Paediatric Immunology, Head, Rare Diseases Theme Head, , University College London, Institute of Child Health

Tim Miller

Tim Miller, President & CEO, Abeona Therapeutics

clock

14:50

Afternoon Tea

clock

15:30

Gene therapy for rare diseases – what we can expect in 2016

Tim Miller

Tim Miller, President & CEO, Abeona Therapeutics

• Multiple groups moving rare disease gene therapies into Phase I and II clinical trials
• The gene therapy bubble – 2013-2015 saw large investments in gene therapy companies
• Manufacturing – the next big hurdle on the path to commercialization
 

clock

16:10

Developing gene therapy for orphan disease indications - a perspective from academia

Professor Bobby Gasper

Professor Bobby Gasper, Professor of Paediatrics and Immunology, Consultant in Paediatric Immunology, Head, Rare Diseases Theme Head, , University College London, Institute of Child Health

• Gene therapy shows significant efficacy in a number of inherited bone marrow disorders
• These are possible curative genetic medicines for otherwise untreatable diseases
• The move beyond academic clinical trials is still difficult and not yet well charted
• There is increasing interest from industry but the commercial case for rare diseases remains difficult
 

clock

16:50

Chairman’s Closing Remarks and Close of Day One

Dr Nicolas Sireau

Dr Nicolas Sireau, Chairman and CEO, AKU Society

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Alastair Kent OBE

Alastair Kent OBE, Director, Director Genetic Alliance UK, Chair of Rare Disease UK (RDUK)

clock

9:10

Putting patients on the team to improve therapy development

Alastair Kent OBE

Alastair Kent OBE, Director, Director Genetic Alliance UK, Chair of Rare Disease UK (RDUK)

• Adaptive Pathways and other innovations will require real world evidence collection
• Patients and families have views on what matters that need to be included
• The benefit:risk  estimation cannot be undertaken effectively without patient input
• Demonstrating value and clinical benefit relies on patient and family experiences being systematically incorporated into MA and HTA processes

 

clock

9:50

Patient-empowered pharmaceutical R & D

Dr Didier Caizergues

Dr Didier Caizergues, Head of regulatory Affairs Department, International Regulatory Affairs department, GENETHON

• The role of patients association in the rare disease field
• The development of an ATPM (gene therapy) as an orphan drug
 

clock

10:30

Morning Coffee

clock

11:00

Meeting the challenges of rare diseases - a big pharma perspective

David Boothe

David Boothe, Global Commercial Leader – GSK Rare Diseases, GSK

o Listening to patients, care givers and patient groups
o Creative development program design
o Open and early engagement with regulators
 

clock

12:20

Networking Lunch

clock

13:30

The importance of building commercial considerations into orphan drug development from the start

John Maddox

John Maddox, Managing Director, Infusion Pharma Consulting LLC

• Why it’s vital to build commercial considerations into orphan drug development  
• Evidencing value to support reimbursement without compromising the trial
• The challenge of multi-indication products
• Supporting early market development efforts 

clock

14:10

The complexity and peculiarities of developing and commercializing advance therapies (ATMPs) for the treatment of rare diseases

Dr Diego Ardigo

Dr Diego Ardigo, ATMP Project Leader, Corporate Drug Development, R&D, Chiesi Farmaceutici S.p.A.

• The complexity of translating “traditional” pharma development into ATMP’s…
o … when pharmacology (primary, secondary, safety), toxicology, DMPK, and carcinogenicity are “not applicable” and phase I simply not existing
o … when late stage clinical studies inevitably carry over development risks from untraditional  CMC, pre-clinical, and early clinical stages
• Understanding the complexity … of logistics in ATMPs with short shelf-life, requiring delicate transportation conditions, or manufactured/ packaged for an individual patient
• The complexity … of market access and pricing for treatments to be administered once in a lifetime
• The return-of-investment in the orphan ATMP space

 

clock

14:50

Afternoon Tea

clock

15:30

Panel Discussion: The Future of Orphan Drugs: Creating an orphan market for a sustainable future

Tim Miller

Tim Miller, President & CEO, Abeona Therapeutics

• Discussing whether the market sustainable
• How can we prepare for the future, what future steps are needed
 

clock

16:10

Opportunities and challenges for biotech companies developing orphan drugs

Anders Waas

Anders Waas, Chief Executive Officer, Tikomed

• Strategy and tactics on the way – focus vs building a pipeline
• Effective drug development and research
• Partnering focus and timing of deals
 

clock

16:50

Chairman’s Closing Remarks and Close of Day Two


Director
Director Genetic Alliance UK, Chair of Rare Disease UK (RDUK)
Chief Executive Officer
Tikomed
Chief Executive
MPS Society UK
Global Commercial Leader – GSK Rare Diseases
GSK
Chief Medical Officer
Orphazyme
Head of regulatory Affairs Department, International Regulatory Affairs department
GENETHON
ATMP Project Leader, Corporate Drug Development, R&D
Chiesi Farmaceutici S.p.A.
Head of Rare Disease Alliances, Rare Disease Research Unit
Pfizer
Chairman and CEO
AKU Society
Vice President of Nursing
The Medical Research Network
Managing Director
Infusion Pharma Consulting LLC
Professor of Paediatrics and Immunology, Consultant in Paediatric Immunology, Head, Rare Diseases Theme Head,
University College London, Institute of Child Health
Founder
DORPHAN S.A., Switzerland
CEO
The Ultra Rare Diseases, Disorder & Disabilities Foundation
President & CEO
Abeona Therapeutics

Sponsors and Exhibitors

Supporters

Who is attending Orphan Drugs and Rare Diseases 2015?

Download

Interview with Terece Hoey, CEO, The Ultra Rare Diseases Disorders & Disabilities Foundation Ltd

Download

Interview with Dr. Stéphane Demotz

Download

Sponsors and Exhibitors


INC Research

Sponsors and Exhibitors
http://www.incresearch.com/

INC Research (Nasdaq: INCR) is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries.


Medical Research Network

Sponsors and Exhibitors
http://www.themrn.co.uk

MRN specializes in the conduct of clinical trial visits in the patient’s home and supporting clinical trial sites with nursing resources. Patients with rare and orphan diseases are often located far from clinical sites and experience debilitating symptoms; our services reduce their travel burden, thus increasing patient recruitment and retention.

Media Partners


Gate2Biotech

Supporters
http://www.gate2biotech.com

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


GBI

Supporters
http://www.gbihealth.com/

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


CanBiotech

Supporters
http://www.canbiotech.com

CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


Pharmiweb

Supporters
http://www.pharmiweb.com

Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


pharmaphorum

Supporters
http://www.pharmaphorum.com

pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


Journal of Rare Disorders

Supporters
http://www.journalofraredisorders.com

The Journal of Rare Disorders (JORD) is a new peer-reviewed, open access publication. The Journal focuses on all aspects of rare diseases, the science, progress on new therapies, new drugs, and issues of drug regulation and cost. There are no fees to publish and we offer viewers barrier free full text articles for download.


Drug Development Technology

Supporters
http://www.drugdevelopment-technology.com

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


Medical News Today

Supporters
http://www.medicalnewstoday.com

Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


Pharmavision

Supporters
http://www.pharmavision.co.uk

PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


Technology Networks

Supporters
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


Select Science

Supporters
http://www.selectscience.net/

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


Global Biodefense

Supporters
http://www.globalbiodefense.com/

Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.


BioMed Central

Supporters
http://www.biomedcentral.com

BioMed Central is an online STM publisher of more than 270 peer-reviewed open access journals. The portfolio of journals spans all areas of biology, biomedicine and medicine, with many journals publishing content related to pulmonary medicine and allergy research. Examples of such journals include: COPD Research and Practice, Multidisciplinary Respiratory Medicine, Respiratory Research, and Allergy, Asthma & Clinical Immunology. All original research articles published by BioMed Central are made freely accessible online immediately upon publication. Authors publishing with BioMed Central retain copyright of their work, licensing it under the Creative Commons Attribution License which allows articles to be re-used and re-distributed without restriction, as long as the original work is correctly cited. BioMed Central is owned by Springer Science+Business Media, and also hosts the SpringerOpen platform.


One Nucleus

Supporters
http://www.onenucleus.com

Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers.


ASD MEDIA

Supporters
http://www.asd-network.com

Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
  • Be informed on the latest market developments; www.asd-network.com
  • Find the latest business news; www.asd-network.com
  • Find the upcoming events; www.asd-network.com
  • Find companies and organizations; www.asdsource.com
  • Distribute news globally. www.asdwire.com
The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

For more detailed information please contact with: ASD MEDIA
Stefan.koopman@asdmedia.nl


British Pharmacological Society

Supporters
http://www.bps.ac.uk

The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects. Clinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.


PharmaVOICE

Supporters
http://www.pharmavoice.com

PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


The Royal Society of Chemistry

Supporters
http://www.rsc.org/

The Royal Society of Chemistry is an international publishing and knowledge business which is the UK’s professional body for chemical scientists; supporting and representing members and bringing together scientists from all over the world. It is a not-for-profit organisation and has an ambitious international vision for the future. It also advises governments on policy and promotes the talent, information and ideas that lead to great advances in science.


PMR

Supporters
http://www.pmrcorporate.com

PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


Antibodies Online

Supporters
http://www.antibodies-online.com

antibodies-online.com facilitates researchers to find the appropriate antibodies for their respective research project. As an independent and multi-vendor marketplace for research antibodies and thanks to the cooperation with more than 130 different manufacturers, a large selection of Antibodies (over 700,000), ELISA Kits (over 130,000), Secondary Antibodies (17,000), Proteins (130,000), Peptides and Isotype Controls is available. By supporting the Independent Validation Initiative and the Resource Identification Initiative, antibodies-online.com also addresses the important topics of transparent product quality and scientific reproducibility. In addition scientists receive news and detailed information about the individual antibodies from databases such as the PubMed and others.


Pharmaceutical Technology

Supporters
http://www.pharmaceutical-technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


Samedan

Supporters
http://www.samedanltd.com/magazine/13.

International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


Contract Biotechnology

Supporters
http://www.contract-biotechnology.com

Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. It is an online R&D matching tool that connects Scientifics and service and product providers worldwide. The platform Contract-Biotechnology.com would help you in the process of finding the right partner saving time and money, because with one single and secure application you would be able to receive multiple quotes quickly, keeping your contact information confidential. Contract-Biotechnology.com is the new Collaboration Network Model for Discovery Research and Development. Contract-Biotechnology.com team has extensive experience working for pharmaceuticals, biotechs, universities and academic research institutes and can help you addressing your key gaps.


Chemoinformatics: Directions Toward Combating Neglected Diseases

Supporters
http://ebooks.benthamscience.com/book/9781608051830/

Computers are an essential tool in modern medicinal chemistry. Currently, these powerful computational tools allow one to obtain insights on the interaction between enzyme-substrate, reaction mechanisms, statistical behavior of molecules and much more, at the molecular level, contributing significantly to solve problems in biological systems. Chemoinformatics: Directions Toward Combating Neglected Diseases explores an open problem in academic literature with a stimulating discussion on the state of the art knowledge in this important research field with respect to neglected diseases, pointing out perspectives on using molecular modeling and theoretical approaches. This eBook is a handy reference guide for anyone who is interested in or deals with medicinal chemistry focused on neglected diseases, from students to advanced researchers.


KONGPOSH Publications

Supporters
http://www.kppub.com

KONGPOSH Publications is one of India’s leading Pharma Publishers. The Pharma Review® is a bi-monthly article based journal covering various fields of pharmacy. Participation and distribution in over 30 Expos & Conferences worldwide each year. It is widely read by decision makers, middle management and the academia. Also available in E-book format. Other publications : Indian Pharma Reference Guide (Annual) – Names and address of Pharmaceuticals, Bulk Drugs, Machinery’s & Instrumentation, AYUSH Manufacturers; and much more; High Performance Thin Layer Chromatography; Elements of Pharmacovigilance; Regulation of Clinical Trials; AYUSH (CD); NDDS/AMD (CD)


Bentham Science

Supporters
http://www.benthamscience.com/

Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


All Conferences

Supporters
http://www.AllConferences.Com

Is a directory focusing on conferences, conventions, trade shows, exhibits, workshops, events and business meetings. This is a unique search directory that serves users looking for specific information on conference or event information; while at the same time provides services to the meeting planners, such as online registrations and payment processing. We are dedicated to providing our end users with high-quality conference information with a comprehensive search engine. The information ranges from specialized scientific, medical and academic conferences to all kinds of general events.

Holiday Inn Regents Park

Carburton Street
London W1W 5EE
United Kingdom

Holiday Inn Regents Park

Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download

Title


Description

Download

Title


Description


Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

Group Booking

Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SAE Media Group

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smgconferences.com Email: events@saemediagroup.com
Registered in England - SMi Group Ltd trading as SAE Media Group




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SAE Media Group.
Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

Fill in your details to download the brochure

By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.